Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
STAAR Surgical (NASDAQ: STAA) issued a March 3, 2026 shareholder letter outlining a reset after a difficult 2025 and a plan to drive revenue growth, profit expansion, and faster innovation in 2026.
The company cites China inventory normalization, Swiss manufacturing ramp, cost reductions beating a $225M second‑half run rate target, EVO+ China approval and shipments, and FDA age expansion for EVO ICL as key catalysts.
STAAR Surgical (NASDAQ: STAA) reported Q4 2025 net sales of $57.8M (+18.1% Y/Y) and fiscal 2025 net sales of $239.4M (-23.7% Y/Y). Gross margin improved to 75.7% Q4; Adjusted EBITDA was breakeven in Q4 versus a prior loss. Cash and investments totaled $187.5M, with no debt and ongoing share repurchase capacity.
The company cites China inventory normalization and EVO+ ICL launch as drivers for expected 2026 growth and announced interim co-CEOs and an external CEO search.
STAAR Surgical (NASDAQ: STAA) announced it has surpassed 4 million Implantable Collamer Lenses (ICLs) sold worldwide, marking accelerating adoption of lens-based refractive correction over laser-based procedures. The company cited expanded regulatory indications, growing real-world evidence, and long-term clinical outcomes as drivers of broader patient access.
STAAR reported ICLs implanted since 1993, sales milestones at 1M (2019), 2M (2022), 3M (2024), and noted sales in over 85 countries with an average ICL patient age of 32 (2025).
STAAR Surgical (NASDAQ: STAA) will release fourth quarter and fiscal year 2025 financial results on March 3, 2026 after market close and host an earnings call and webcast at 5:30 p.m. ET.
Topics include fiscal 2025 operations, China recovery, inventory normalization, cost discipline, Switzerland manufacturing expansion, innovation pipeline, and 2026 strategic focus. A replay will be available for at least 90 days.
STAAR Surgical (NASDAQ: STAA) announced the FDA expanded the U.S. age indication for EVO/EVO+ Visian ICL to 21–60 years, widening the addressable market by nearly 8 million U.S. adults. The decision follows three-year FDA trial data (629 eyes) showing a safety index of 1.25 and a 0.16% anterior subcapsular cataract incidence. Market data cited a ~40% decline in laser corneal procedures over three years and that EVO ICL accounted for 72% of procedures in patients with ≤-8.0 D, signaling a shift toward lens-based correction.
STAAR Surgical (NASDAQ: STAA) appointed Warren Foust, President and COO, and Deborah Andrews, CFO, as interim co‑CEOs, effective February 1, 2026.
The Board said both will lead day‑to‑day operations while a Board‑appointed Search Committee has initiated a global search for a permanent CEO, engaging executive search firms and evaluating internal and external candidates.
STAAR Surgical (NASDAQ: STAA) and activist investor Broadwood Partners entered a cooperation agreement effective January 15, 2026, after Broadwood disclosed ownership of 31% of STAAR and Yunqi Capital disclosed 6.5%. Broadwood principals Neal C. Bradsher and Richard T. LeBuhn and Christopher Wang of Yunqi joined STAAR's Board immediately, expanding the Board from six to seven members. Chair Elizabeth Yeu and Director-Board member CEO Stephen Farrell stepped down from the Board; Farrell will remain CEO until January 31, 2026. The company said the Board will announce a new Chair and CEO in the near term and will file the Cooperation Agreement as an exhibit to a Form 8-K.
Alcon (SIX/NYSE: ALC) announced on January 7, 2026 that it has terminated its definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) that was announced on August 5, 2025. The company said it remained disciplined on price and risk and that its refractive strategy is unchanged, with a continued focus on its wavelight® plus offering for LASIK.
Alcon also said it will continue global launches of more than 10 major products across surgical and vision care this year and reiterated forward-looking caution about uncertainties and risks.
Broadwood Partners, which owns 30.2% of STAAR common stock (NASDAQ: STAA), thanked shareholders after preliminary results from the January 6, 2026 Special Meeting showed a decisive vote to reject the proposed acquisition of STAAR by Alcon (NYSE: ALC). Broadwood reiterated confidence in STAAR’s standalone prospects, citing leading technology, a strong financial position, large market opportunities, and a path to margin expansion.
Broadwood said it is ready to engage with the board and fellow shareholders to implement changes aimed at improving oversight and execution to help STAAR pursue growth and profitability as an independent company.
STAAR Surgical (NASDAQ: STAA) announced preliminary results from its Special Meeting of Stockholders on January 6, 2026 showing it did not receive the required votes to approve the merger with Alcon. STAAR intends to terminate the merger agreement. No termination fee will be payable by either party. STAAR will remain a standalone, publicly traded company and continue to trade on Nasdaq under the ticker STAA. Final certified results will be filed in a Form 8-K with the SEC.